Project Grant R01CA294365
Award Date
2/1/25
Completion Date
1/31/30
Dollars Obligated
$658K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Houston, TX 77204, USA
Similar Awards
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research aimed at improving treatment of a subset of childhood rhabdomyosarcoma (RMS) cancer. The $482,175 grant, awarded on July 1, 2024, will fund a 5-year project led by the University of California, San Francisco (UCSF) to study the molecular basis for how a specific oncogenic fusion protein (PAX3-FOXO1) drives RMS tumor growth, and to develop...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) will support the development and characterization of genetically engineered mouse models (GEMMs) that replicate key features of human high-risk rhabdomyosarcoma (RMS). The $194,013 award to Sanford Research aims to explore aberrant activation of the NOTCH1 pathway as both a driver and potential therapeutic target for this aggressive pediatric soft tissue cancer....
This $148,500 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the role of the protein kinase PBK in driving tumor growth and metastasis in triple-negative breast cancer (TNBC). The research, conducted by the University of Alabama at Birmingham, aims to determine the in vivo effects of PBK inhibition on TNBC tumor growth and metastasis, as well as evaluate the efficacy of a PBK inhibitor for TNBC treatment. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports preclinical research on a novel tumor-agnostic theranostic approach targeting transforming growth factor beta (TGFβ) for cancer therapy. The University of California, San Francisco (UCSF) will receive $676,567 over the project period from December 2024 to November 2029 to conduct this research. The goal is to evaluate the biological effectiveness and tumor response of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop and evaluate novel inhibitors of the NSMASE2 protein as a potential therapeutic strategy to enhance the efficacy of immune checkpoint inhibitors in cancer treatment. The total award amount is $695,916 over a 5-year period starting September 1, 2024. The key products and services to be delivered under this award include: Synthesizing and optimizing PDDC...
This $491,826 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the University of Texas Southwestern Medical Center (UT Southwestern) aims to investigate the role of the cancer-testis antigen Testis-Specific Serine Kinase 6 (TSSK6) in colorectal cancer progression and drug resistance. The 5-year research project will: 1) comprehensively examine how TSSK6 signaling at focal adhesions influences tumor cell invasion, survival, and chemotherapeutic...
This $180,632 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to discover and validate compounds that can block cancer cell engulfment of mesenchymal stem cells, which has been linked to increased metastatic potential in breast cancer. The two-year project, running from May 2025 to April 2027, will leverage high-throughput microfluidic technology to conduct a comprehensive screening of 2,726 compounds with...
This $514,405 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by Sanford Research, a non-profit biomedical research organization, to investigate the mechanisms underlying the role of cancer-dependent skeletal pathways in the development and progression of osteosarcoma. The research aims to: 1) Elucidate the role of cancer-dependent skeletal genes and pathways in osteoblast-specific p53 and Rb loss-of-function models,...
This Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program provides $218,089 to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel Rac-Enhanced Chimeric Antigen Receptor Macrophage (RACE-CAR-M) immunotherapy for triple-negative breast cancer (TNBC). The key products and services to be delivered under this 4/1/2025 to 3/31/2027 award include: Evaluating the specificity, efficacy, and anti-angiogenic potential of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel therapeutic strategy targeting mutant p53, a gene known to drive tumor progression, metastasis, and therapy resistance in more than half of human cancers. The $590,625 award to the University of California, Davis (UC Davis) will fund a 5-year project (3/1/2025 - 2/28/2030) to investigate how the CDK4/6-RBM38-eIF4G axis regulates mutant p53 expression,...